Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Sanofi Dupixent wins USFDA nod for atopic dermatitis

Ruchika Sharma8 Jun 2022 1:00 PM IST

Dupixent is administered as an injection under the skin (subcutaneous injection) at different injection sites.

Novavax COVID shot gets USFDA Advisory Committee recommendation for emergency use nod for 18 years and older

Ruchika Sharma8 Jun 2022 12:14 PM IST

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

SII to produce Novavax COVID vaccine for US

Ruchika Sharma8 Jun 2022 10:00 AM IST

New Delhi: Novavax Inc said on Tuesday that its COVID-19 vaccine initially available in the United States, if authorized, will be manufactured by the...

JnJ to terminate COVID vaccine agreement with Emergent BioSolutions

Ruchika Sharma7 Jun 2022 4:33 PM IST

If the agreement is terminated, Emergent said J&J would owe it roughly $125 million to $420 million.

Pristyn Care acquires online consultation platform Lybrate

Ruchika Sharma7 Jun 2022 3:48 PM IST

With this acquisition, Pristyn Care is looking to add doctor consultation online services, improve care effectiveness in primary care and meet patient...

Novartis intrathecal onasemnogene abeparvovec Phase III study

Novartis Tafinlar, Mekinist combination shows promise in childhood brain cancer

Ruchika Sharma7 Jun 2022 3:22 PM IST

The trial only included those who were found to have a mutation known as BRAF V600, a genetic contributor in about 15% to 20% of pediatric LGG cases.

Zydus Lifesciences Topical acne treatment gel gets USFDA okay

Ruchika Sharma7 Jun 2022 1:10 PM IST

The drug will be manufactured at group’s topical facility at Ahmedabad.

Aurobindo Pharma arm bags USFDA nod for Leuprolide Acetate Injection

Ruchika Sharma7 Jun 2022 12:46 PM IST

Leuprolide Acetate for injection is indicated for the treatment used to treat the symptoms associated with advanced prostate cancer by way of...

Zaara Biotech scoops up investment from Transcend International

Ruchika Sharma7 Jun 2022 11:50 AM IST

The startup has also manufactured India’s first algal seaweed cookies, including high protein algal Spirulina cookies.

Delhi HC Restrains Use of CALDIMUST Trademark Deceptively Similar to Mankinds CALCIMUST

Mankind Pharma to establish pet food manufacturing facility in Telangana

Ruchika Sharma7 Jun 2022 10:00 AM IST

The company will invest Rs 159 Crores to establish a manufacturing plant.

Gilead Sciences drug Trodelvy modestly delays breast cancer progression in late-stage trial

Ruchika Sharma6 Jun 2022 4:09 PM IST

Wall Street analysts, on average, expect annual sales of the drug will top $2 billion 2026, according to Refinitiv.

GSK application to expand use of Nucala for COPD accepted for review by EMA

GSK Measles vaccine Priorix bags USFDA okay

Ruchika Sharma6 Jun 2022 3:00 PM IST

Measles, mumps and rubella are acute and highly-contagious viral diseases responsible for considerable morbidity and mortality throughout the world.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok